Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
75,000
Employees75,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
75,000
Employees75,000

MRK Key Statistics

Market cap
260.22B
Market cap260.22B
Price-Earnings ratio
13.87
Price-Earnings ratio13.87
Dividend yield
3.09%
Dividend yield3.09%
Average volume
18.18M
Average volume18.18M
High today
$105.41
High today$105.41
Low today
$104.12
Low today$104.12
Open price
$104.84
Open price$104.84
Volume
6.15M
Volume6.15M
52 Week high
$105.84
52 Week high$105.84
52 Week low
$73.31
52 Week low$73.31

Stock Snapshot

With a market cap of 260.22B, Merck(MRK) trades at $104.62. The stock has a price-to-earnings ratio of 13.87 and currently yields dividends of 3.1%.

As of 2025-11-30, Merck(MRK) stock has fluctuated between $104.12 and $105.41. The current price stands at $104.62, placing the stock +0.5% above today's low and -0.7% off the high.

The Merck(MRK)'s current trading volume is 6.15M, compared to an average daily volume of 18.18M.

During the past year, Merck(MRK) stock moved between $73.31 at its lowest and $105.84 at its peak.

During the past year, Merck(MRK) stock moved between $73.31 at its lowest and $105.84 at its peak.

MRK News

The Motley Fool 7h
These Underrated Companies Could Be "Training-Wheels" Stocks for Long-Term Wealth Builders

If you are thinking in decades and not days, this trio of dividend stocks could be the perfect starting point for your fledgling portfolio. If investing were e...

These Underrated Companies Could Be "Training-Wheels" Stocks for Long-Term Wealth Builders
Simply Wall St 11h
A Look at Merck's Valuation as Shares Gain Momentum

Merck (MRK) shares have picked up some steam this week, trading higher over the past month. Investors are taking note as the company maintains a steady growth p...

A Look at Merck's Valuation as Shares Gain Momentum
Nasdaq 18h
Should You Buy This Blue Chip Pharmaceutical Stock That Just Popped 3.8%?

Key Points One of Merck's key assets has just scored a significant phase 2 win, boosting investor confidence. This adds to other recent developments that coul...

Should You Buy This Blue Chip Pharmaceutical Stock That Just Popped 3.8%?

Analyst ratings

55%

of 29 ratings
Buy
55.2%
Hold
44.8%
Sell
0%

More MRK News

Nasdaq 3d
Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth?

Bristol Myers BMY has a robust oncology portfolio, including the blockbuster immune-oncology drugs, Opdivo, Opdivo Qvantig and Yervoy, among others. Opdivo is...

Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth?
Nasdaq 3d
AstraZeneca or Merck: Which Oncology Giant Has the Edge?

AstraZeneca AZN and Merck MRK are both major global pharmaceutical companies with diversified drug portfolios. While Merck is a U.S.-based company, AstraZeneca’...

AstraZeneca or Merck: Which Oncology Giant Has the Edge?
Nasdaq 3d
Investors Heavily Search Merck & Co., Inc.: Here is What You Need to Know

Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influenc...

Investors Heavily Search Merck & Co., Inc.: Here is What You Need to Know
Nasdaq 4d
Merck Reaches Analyst Target Price

In recent trading, shares of Merck & Co Inc (Symbol: MRK) have crossed above the average analyst 12-month target price of $92.07, changing hands for $92.32/shar...

Merck Reaches Analyst Target Price
Simply Wall St 4d
Merck Is Up 9.6% After Keytruda-Padcev Combo Wins FDA Nod for Bladder Cancer

Merck received FDA approval for Keytruda (including the new subcutaneous Keytruda QLEX) in combination with Padcev for use before and after surgery in adults wi...

Merck Is Up 9.6% After Keytruda-Padcev Combo Wins FDA Nod for Bladder Cancer
TipRanks 6d
Merck to present hematology pipeline data at ASH meeting

Merck (MRK) announced that new data across multiple hematologic malignancies will be presented at the American Society of Hematology Annual Meeting and Expositi...

TipRanks 6d
Merck upgraded to Overweight from Equal Weight at Wells Fargo

Wells Fargo upgraded Merck (MRK) to Overweight from Equal Weight with a price target of $125, up from $90. Following recent business development, pipeline progr...

People also own

Based on the portfolios of people who own MRK. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.